Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

4th year Oxford Medical School student Alex Grassam-Rowe’s writes on his admiration and respect for colleagues and others pulling together in the fight against COVID-19

There were nervous discussions amongst us medics on placement where the first UK COVID-19 death was. Shortly after, normality gave way to the surreal.

A foundation doctor, barely a few years older than me, calmly told us where on the ward to not go as they were COVID ‘hot zones’. The other student and I shot each other looks of surprise. When I then attended the talk from the hospital Executive team, I was stunned further – the infamous management vs clinician dynamics had evaporated.

Overnight, we had become superfluous medical students on the frontline of a global pandemic. Us practising how to feel a tummy was redundant as our teachers were needed to treat those filling the ward. We all packed up, handed in our ID badges, and were bundled into shared cars. The security guard who I gave the ID badges to wished us luck back at the John Radcliffe, and I wished them luck here.

Upon return to Oxford, the collaborative spirit and bravery here impressed me greatly. Heeding our Division’s call for clinically trained staff, healthcare workers have returned to practice, and final year medical students joined in.

Within days our own community had begun the development of rapid and easy-to-use test kits, novel designs for ventilators, and vaccine trials – joining scientists across the globe helping to fight COVID.

As a fledgling ‘scientist’ I was used to certain timeframes – e.g. vaccines taking years, even decades, to get out. I know that through the dedication, mental effort, and hours of pipetting, our fantastic scientists are working tirelessly to reduce those timeframes to a matter of months to help protect those most vulnerable all around the globe.

Taken away from my placement and COVID hot spot wards, I’m instead sat typing this from my room in Oxford looking out over some hills. The disruption to my life is relatively minimal. SARS-CoV2 remains a concept; COVID another disease I now have to know the ins and outs of, but won’t know what it’s really like to treat someone with. This is now the responsibility and challenge facing our healthcare workers and scientists - our real-life heroes whom we owe so much.

And yet, I don’t feel helpless. Beyond those who can help on the ‘frontline’ in patient-facing roles, our wider community has risen to the challenge.

Medical Sciences students have been key in orchestrating community support networks, within the University and within Oxford – barriers of town and gown melting away. I have known heart scientists turn their hands to viral protein-drug interactions, medics turn to childcare, and I have seen our students, our SU, our Colleges, our Departments, our Divisions, our University, our wider community, have all come together. I hope that many years from now we can still recall the collaboration across all walks of life that helped see humanity through.

Whenever friends or family ask, I am proud to tell them with sincerity that work here in our Division is leading the fight for all of humanity. I have been struck by the courage, collaboration, and adaptability of healthcare workers around the world, and those supporting them. I can only hope my teachers, colleagues, and friends know how proud I am of them.

You are whom I envisioned when my younger self dreamt of becoming a doctor.

Similar stories

Singula Bio, a new Oxford spin-out company - Cancer need not be fatal

General Innovation Research

Singula Bio, a bold new seed-stage biotechnology company spun out of Oxford University, has been launched with the intention of helping show that cancer need not be fatal. Led by three Oxford cancer specialists, the firm is aims to become a world leader in therapies to use against difficult-to-treat solid malignancies such as ovarian cancer - using the body’s own immune system to fight previously fatal cancers.

Major rise in public support for COVID vaccine – Oxford study

Coronavirus COVID-19 General Research

More than three quarters of people in the UK now say they are ’very likely’ to have the vaccine – up from 50% among the same group of survey respondents five months ago –according to a two-wave Oxford University survey published today.

Coronavirus vaccination linked to substantial reduction in hospitalisation, real-world data suggests

Coronavirus COVID-19 General Research

The first study to describe the effects in real-world communities of the Oxford coronavirus vaccine has been reported in a pre-print publication today, showing a clear reduction in the risk of hospitalisation from COVID-19 amongst those who have received the vaccine.

World’s largest clinical trial for COVID-19 treatments expands internationally

Clinical Trials Coronavirus COVID-19 General

The Randomised Evaluation of COVID-19 Therapy (RECOVERY) Trial, the world’s largest clinical trial for COVID-19 treatments, has now expanded internationally with Indonesia and Nepal among the first countries to join. The first patients have been recruited to RECOVERY International.

Reprogramming tumour cells using an antimalarial drug

General Research

Results from the ATOM clinical trial at the University of Oxford have shown that the anti-malarial drug Atovaquone can reduce very low oxygen tumour environments. This has the potential to make cancers behave less aggressively and to improve the impact of everyday cancer treatments.